AP Biosciences

AP Biosciences EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AP Biosciences (6945.TWO) as of Nov 17, 2026 is -456.38 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -438.39 M TWD — a change of 4.10% (lower).

EBITDA

-456.38 MTWD

YoY

4.10%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AP Biosciences is 2025 -456.38 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AP Biosciences was 2024 -438.39 M TWD. It decreases by 4.10% lower compared to the previous year.

The AP Biosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
45.78 M TWD
Jan 1, 2021
-185.73 M TWD
Jan 1, 2022
-286.77 M TWD
Jan 1, 2023
-345.98 M TWD
Jan 1, 2024
-438.39 M TWD
Jan 1, 2025
-456.38 M TWD
The AP Biosciences EBITDA history
YEAREBITDAYoY
-456.38 MTWD+4.10%
-438.39 MTWD+26.71%
-345.98 MTWD+20.65%
-286.77 MTWD+54.40%
-185.73 MTWD-505.74%
45.78 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AP Biosciences is -456.38 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of AP Biosciences changed from -438.39 M TWD to -456.38 M TWD, representing a 4.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AP Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AP Biosciences

All Key Metrics — AP Biosciences